Quantification of Human Adipogenesis
This study is currently recruiting participants.
Verified September 2011 by Brigham and Women's Hospital
Sponsor:
Brigham and Women's Hospital
Information provided by (Responsible Party):
Todd Perlstein, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01257997
First received: December 9, 2010
Last updated: September 26, 2011
Last verified: September 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is using a novel technology to measure the rate of turnover of new fat cells. It involves a 2-night stay in the hospital, and 2 fat biopsies. The fat biopsies will be looked at under a special microscope that can tell which fat cells have been recently made.
| Condition | Intervention |
|---|---|
|
Healthy Subjects |
Biological: 15N-Thymidine |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Quantification of Human Adipogenesis |
Further study details as provided by Brigham and Women's Hospital:
Primary Outcome Measures:
- Quantifying human adipogenesis-counting the number of new fat cells. [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Fat biopsy. Mucosal smear. White blood cells.
| Estimated Enrollment: | 6 |
| Study Start Date: | December 2010 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Healthy subjects
18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body ass index from 20 to 27. Must be able to easily 'pinch an inch' of belly fat.
|
Biological: 15N-Thymidine
Stable isotope 15N-Thymidine, 750 mg, infused IV for 48 hours.
|
Eligibility| Ages Eligible for Study: | 18 Years to 49 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Healthy volunteers. Aged 18-49 years. Free of significant chronic medical illness. Free of illicit substance abuse.
Criteria
Inclusion Criteria:
- Aged 18-49 years.
- Healthy.
Exclusion Criteria:
- Significant chronic medical illness.
- Illicit substance abuse.
- Body mass index > 27 kg/meters squared.
- Underweight (BMI < 20 kg/m2).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01257997
Contacts
| Contact: Todd S Perlstein, MD | 617 732 5500 ext 34358 | tperlstein@partners.org |
| Contact: Matthew Steinhauser, MD | 617 732 5500 ext 13202 | MSTEINHAUSER@PARTNERS.ORG |
Locations
| United States, Massachusetts | |
| Brigham and Women's Hospital | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Contact: Todd S Perlstein, MD 617-732-5656 ext 34358 tperlstein@partners.org | |
| Contact: Matthew Steinhauser, MD 617 732 5656 ext 13202 MSTEINHAUSER@PARTNERS.ORG | |
Sponsors and Collaborators
Brigham and Women's Hospital
More Information
No publications provided
| Responsible Party: | Todd Perlstein, MD, Associate Physician, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT01257997 History of Changes |
| Other Study ID Numbers: | BWH-2010p001900 |
| Study First Received: | December 9, 2010 |
| Last Updated: | September 26, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Brigham and Women's Hospital:
|
No specific experimental conditions |
ClinicalTrials.gov processed this record on May 23, 2013